

Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

Brilliant Violet 711(TM) anti-human CD8a

RRID:AB_2562906

Type: Antibody

Proper Citation

BioLegend Cat# 301044, RRID:AB_2562906

Antibody Information

URL: http://antibodyregistry.org/AB_2562906

Proper Citation: BioLegend Cat# 301044, RRID:AB_2562906

Target Antigen: CD8alpha

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-human CD8a

Description: This monoclonal targets CD8alpha

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone RPA-T8

Antibody ID: AB_2562906

Vendor: BioLegend

Catalog Number: 301044

Alternative Catalog Numbers: 301043

Record Creation Time: 20250819T234248+0000

Record Last Update: 20250820T061110+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-human CD8a.

No alerts have been found for Brilliant Violet 711(TM) anti-human CD8a.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Umhoefer JM, et al. (2026) FOXP3 expression depends on cell-type-specific cis-regulatory elements and transcription factor circuitry. *Immunity*, 59(1), 129.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. *Immunity*, 59(7), 1928.

Hamm F, et al. (2025) DNA methylomes undergo distinct waves of remodeling during thymic T cell development and do not acquire a proliferation-induced imprint. *Cell reports*, 44(8), 116092.

Benmebarek MR, et al. (2025) Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. *Immunity*, 58(4), 926.

Touizer E, et al. (2023) Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. *iScience*, 26(1), 105862.

Zwijnenburg AJ, et al. (2023) Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. *Immunity*, 56(8), 1955.

Ciacchi L, et al. (2023) CD4+ T cell-mediated recognition of a conserved cholesterol-dependent cytolysin epitope generates broad antibacterial immunity. *Immunity*, 56(5), 1082.

Gao Y, et al. (2022) Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. *Immunity*, 55(9), 1732.

Mandolesi M, et al. (2021) SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. *Cell reports. Medicine*, 2(4), 100252.

Delacher M, et al. (2021) Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. *Immunity*, 54(4), 702.

Ahmed R, et al. (2020) CD57+ Memory T Cells Proliferate In Vivo. *Cell reports*, 33(11), 108501.

Gurusamy D, et al. (2020) Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. *Cancer cell*, 37(6), 818.

Medler TR, et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. *Cancer cell*, 34(4), 561.

Cale EM, et al. (2017) Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. *Immunity*, 46(5), 777.